



S&amp;H Form: (10/01)

**REPLY/AMENDMENT  
FEE TRANSMITTAL**

Attorney Docket No. 1546.1007  
Application Number 09/995,829  
Filing Date November 29, 2001  
First Named Inventor Ji-Won YOON, et al.  
Group Art Unit 1648

TECH CENTER 1600/2900  
JUL 15 2002

RECEIVED

AMOUNT ENCLOSED

400.00

Examiner Name

Myron G. Hill

**FEE CALCULATION (fees effective 10/01/01)**

CLAIMS AS AMENDED	Claims Remaining After Amendment	Highest Number Previously Paid For	Number Extra	Rate	Calculations
TOTAL CLAIMS	11	- 20 =	0	X \$ 18.00 =	\$ 0.00
INDEPENDENT CLAIMS	2	- 3 =	0	X \$ 84.00 =	0.00

Since an Official Action set an original due date of ., petition is hereby made for an extension to cover the date this reply is filed for which the requisite fee is enclosed (1 month (\$110); 2 months (\$400); 3 months (\$920); 4 months (\$1,440); 5 months

400.00

If Notice of Appeal is enclosed, add (\$320)

If Statutory Disclaimer under Rule 20(d) is enclosed, add fee (\$110)

Total of above Calculations =

\$ 400.00

Reduction by 50% for filing by small entity (37 CFR 1.9, 1.27 &amp; 1.28)

TOTAL FEES DUE =

\$ 400.00

(1) If entry (1) is less than entry (2), entry (3) is "0".

(2) If entry (2) is less than 20, change entry (2) to "20".

(4) If entry (4) is less than entry (5), entry (6) is "0".

(5) If entry (5) is less than 3, change entry (5) to "3".

**METHOD OF PAYMENT**☒ Check enclosed as payment.☐ Charge "TOTAL FEES DUE" to the Deposit Account No. below.☐ No payment is enclosed and no charges to the Deposit Account are authorized at this time (unless specifically required to obtain a filing date).**GENERAL AUTHORIZATION**☒ If the above-noted "AMOUNT ENCLOSED" is not correct, the Commissioner is hereby authorized to credit any overpayment or charge any additional fees necessary to:

Deposit Account No.

19-3935

Deposit Account Name

STAAS &amp; HALSEY LLP

☒ The Commissioner is also authorized to credit any overpayments or charge any additional fees required under 37 CFR 1.16 (filing fees) or 37 CFR 1.17 (processing fees) during the prosecution of this application, including any related application(s) claiming benefit hereof pursuant to 35 USC § 120 (e.g., continuations/divisionals/CIPs under 37 CFR 1.53(b) and/or continuations/divisionals/CPAs under 37 CFR 1.53(d)) to maintain pendency hereof or of any such related application.

SUBMITTED BY: STAAS &amp; HALSEY LLP

Typed Name Michael D. Stein

Reg. No. 37,240

Signature

Date

7/1/02

CERTIFICATE UNDER 37 CFR 200.41 Staas &amp; Halsey LLP

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231

on July 1, 2002  
STAAS & HALSEY LLP  
By: [Signature]

July 1, 2002



Docket No.: 1546.1007

TECH CENTER 1600/2900

JUL 15 2002

RECEIVED

#6A  
PB  
7/18/02

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Ji-Won YOON, et al.

Serial No. 09/995,829

Group Art Unit: 1648

Confirmation No. 9726

Filed: November 29, 2001

Examiner: Myron G. Hill

For: RECOMBINANT VACCINIA INCORPORATED WITH GENE CODING GLUTAMIC ACID  
DECARBOXYLASE AND VACCINE FOR PREVENTING TYPE 1 DIABETES MELLITUS  
COMPRISING THE SAME

AMENDMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

CERTIFICATE UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231

on July 1, 2002

By: STAAS & HALSEY LLP

Date: July 1, 2002

This is in response to the Office Action mailed January 30, 2002, and having a period for response set to expire on April 30, 2002. A Petition for a two-month extension of time, together with the requisite fee for same, is submitted herewith, thereby extending the period for response to June 30, 2002.

The following amendments and remarks are respectfully submitted. Reconsideration of the claims is respectfully requested.

**IN THE SPECIFICATION:**

Please REPLACE the paragraph beginning at page 3, line 5, with the following paragraph:

A1  
In view of the foregoing and to explore the potential of immunogene therapy based on GAD for the prevention of autoimmune diabetes, we developed a recombinant virus which can express GAD and induce humoral and cell-mediated immune response to a target protein, and found that the induced immune responses are long lived.

**IN THE CLAIMS:**

Please REPLACE claims 3 and 4 in accordance with the following:

07/12/2002 AOSMAN1 00000054 09995829

01 FC:116

400.00 OP